Kazia Therapeutics (NASDAQ:KZIA – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Wednesday, Zacks.com reports.
According to Zacks, “Kazia Therapeutics Limited is an oncology-focused biotechnology company. It develops anti-cancer drugs as well as provides pharmaceutical research and development technology solutions. The company’s lead program is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being developed to treat glioblastoma multiforme, the primary and most aggressive form of brain cancer. Kazia Therapeutics Limited, formerly known as Novogen Limited, is based in Sydney, Australia. “
Kazia Therapeutics stock opened at $6.75 on Wednesday. The stock’s fifty day moving average is $7.20 and its two-hundred day moving average is $8.37. Kazia Therapeutics has a 1-year low of $5.79 and a 1-year high of $12.28.
Several institutional investors and hedge funds have recently bought and sold shares of KZIA. Morgan Stanley increased its position in shares of Kazia Therapeutics by 1.4% during the second quarter. Morgan Stanley now owns 233,953 shares of the company’s stock worth $2,307,000 after purchasing an additional 3,152 shares in the last quarter. Citadel Advisors LLC acquired a new stake in shares of Kazia Therapeutics during the second quarter worth about $126,000. Envestnet Asset Management Inc. acquired a new position in Kazia Therapeutics in the 4th quarter valued at about $223,000. Finally, Susquehanna International Group LLP increased its position in Kazia Therapeutics by 107.2% in the 4th quarter. Susquehanna International Group LLP now owns 50,762 shares of the company’s stock valued at $429,000 after acquiring an additional 26,267 shares during the period. Institutional investors and hedge funds own 3.41% of the company’s stock.
Kazia Therapeutics Company Profile (Get Rating)
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer.
See Also
Get a free copy of the Zacks research report on Kazia Therapeutics (KZIA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Want More Great Investing Ideas?
Receive News & Ratings for Kazia Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Kazia Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.
